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Background: Clopidogrel and proton pump inhibitors (PPIs) are metabolized by
cytochrome P450 enzymes. Contradictory results have been reported on possible
complications of simultaneous PPI and clopidogrel use. Our aim was to investigate the
clinical relevance of this debate with a systematic review and meta-analysis.
Methods: The PubMed, Embase, and Cochrane Central Register of Controlled Trials
electronic databases were searched for human studies [randomized controlled trials
(RCTs) and observational studies] using the PICO format (P: patients on clopidogrel; I:
patients treated with PPI; C: patients without PPI treatment; O: cardiovascular risk). We
screened eligible studies from 2009 to 2016. After study exclusions, we extracted data
from 27 articles for three outcomes: major adverse cardiac event (MACE), myocardial
infarction (MI) and cardiovascular (CV) death. The meta-analysis was registered on
PROSPERO (CRD42017054316).
Results: Data were extracted on 156,823 patients from the 27 trials included (MACE:
23, CV death: 10, MI: 14). The risks of MACE (RR = 1.22, 95% CI = 1.06–1.396,
p = 0.004) and MI (RR = 1.43, 95% CI = 1.24–1.66, p < 0.001) were significantly
higher in the PPI plus clopidogrel group. However, subgroup analysis demonstrated that
this significance disappeared in RCTs (RR = 0.99, 95% CI = 0.76–1.28, p = 0.93)
in the MACE outcome group. There was no effect of combined PPI and clopidogrel
therapy on CV death outcome (RR = 1.21, 95% CI = 0.97–1.50, p = 0.09).
Demcsák et al. Clopidogrel Plus PPIs: Cardiovascular Outcomes
Conclusion: Concomitant use of PPIs and clopidogrel has been proved not to be
associated with elevated cardiovascular risks according to RCTs. Based on our results,
no restrictions should be applied whenever PPIs and clopidogrel are administered
simultaneously.
Keywords: proton pump inhibitors, clopidogrel, cardiovascular risk, drug interaction, cytochrome P450, meta-
analysis
INTRODUCTION
The literature consists of contradictory findings on the
concomitant usage of clopidogrel and proton pump inhibitors
(PPIs). A combination of antiplatelet drugs is used for
the treatment of acute coronary syndrome (i.e., aspirin and
thienopyridines) and for the secondary prevention of further
cardiovascular (CV) events (Yusuf et al., 2001). It is well-
documented that dual antiplatelet therapy is followed by possible
side-effects, such as higher risk for gastrointestinal (GI) bleeding
increasing bothmortality and ischaemic complications (Nikolsky
et al., 2009; Disney et al., 2011). To reduce the risk of GI bleeding
in patients with risk factors, PPIs are strongly recommended by
the American College of Cardiology, the American College of
Gastroenterology, and the American Heart Association (Bhatt
et al., 2008; Abraham et al., 2010; Disney et al., 2011). In vitro
findings suggested that PPIs reduce the antiplatelet effect of
clopidogrel (Gilard et al., 2008), followed by several clinical
studies with contradictory outcomes (Pezalla et al., 2008; Ho
et al., 2009; Juurlink et al., 2009; O’Donoghue et al., 2009;
Rassen et al., 2009; Bhatt et al., 2010; Charlot et al., 2010;
Gupta et al., 2010; Hudzik et al., 2010; Kreutz et al., 2010;
Ray et al., 2010; van Boxel et al., 2010; Zairis et al., 2010;
Burkard et al., 2012; Mo et al., 2015; Sherwood et al., 2015).
A higher risk for CV outcomes was found in several studies,
systematic reviews andmeta-analyses in patients with clopidogrel
on PPI therapy. Generally, whenever observational studies were
included, a positive association was described. On the other
hand, whenever propensity-matched groups were compared
the difference between the groups disappeared (Rassen et al.,
2009; Kwok and Loke, 2010; Valkhoff et al., 2011; Chen et al.,
2012; Mo et al., 2015). Therefore, it is clear that a precise
investigation is crucial to understanding the potential CV risk of
co-administration of clopidogrel and PPIs.
MATERIALS AND METHODS
Literature Search
A systematic review of studies was performed in accordance
with the Preferred Reporting Items for Systematic Reviews and
Meta-analysis (PRISMA) Statement (Moher et al., 2015). After
developing our clinical question and translating it into a well-
defined systematic review question based on the PICO format
(Patients, Interventions, Comparators and Outcomes), a manual
Abbreviations: CV, cardiovascular; GI, gastrointestinal; MACE, major adverse
cardiac event; MI, myocardial infarction; PPI, proton pump inhibitor; RCT,
randomized controlled trial; RR, risk ratio/relative risk
search of medical databases, including PubMed (MEDLINE),
Embase, and the Cochrane Central Register of Controlled Trials,
was performed for human observations using the following
PICO format: P: patients on clopidogrel; I: patients treated
with PPI; C: patients without PPI treatment; O: cardiovascular
risk. Two independent investigators (AD and ERB) separately
screened the titles and abstracts for eligible studies published
from inception to 30 December 2016. The flowchart for this
process is shown in Figure 1. After searching the international
prospective register for systematic reviews (PROSPERO) for
ongoing or completed meta-analyses on the examined effects of
PPIs, we registered our present meta-analysis on PROSPERO
under No. CRD42017054316.
Study Selection
Inclusion criteria: (1) randomized or observational studies
(cohort and case-control studies) carried out either in a retro- or
prospective manner; (2) only adult patients (over 18 years); (3)
patients receiving clopidogrel treatment; (4) should compare PPI
takers (omeprazole, pantoprazole, esomeprazole, lansoprazole
and/or rabeprazole; all doses) and non-PPI takers; (5) we
only involved studies that stated exact patient number in the
preferred groups (total number of patients, patients who received
clopidogrel and PPI, outcome number); (6) human studies; (7)
studies should show data for either one or more of the following
outcomes: (1) major adverse cardiac event (MACE): composite of
cardiac and non-cardiac death, non-fatal myocardial infarction,
target vessel failure; (2) myocardial infarction (MI): myocardial
infarction or new, definitive major coronarographic defect; (3)
CV death: only CV death. Studies published in English were
selected. Duplicates were eliminated from the analysis manually.
Disagreements were resolved by consulting a small committee of
three researchers (PeH, JB, and ÁV).
Data Extraction
Numeric and texted data were extracted from the eligible
articles as follows: author, publication year, study type,
study endpoints, number of patients in the study, in PPI
and in non-PPI treatment groups, and number of patients
who received clopidogrel. We also collected the specified
generic name of the PPI and patient number if indicated.
For study characteristics we collected numeric and texted
data as follows: country/region, mean follow up, number
of male patients, mean age and mean body mass index,
other medications (angiotensin-converting enzyme inhibitor,
angiotensin receptor blocker, statin), cardio- and cerebrovascular
history (MI, percutaneous coronary intervention, stroke)
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FIGURE 1 | Flowchart for study selection and inclusion. CV, cardiovascular; MACE, major adverse cardiac event; MI, myocardial infarction; PPI, proton pump inhibitor;
x, full articles were not available by any suitable sources.
and CV risk factors (hypertension, diabetes mellitus,
dyslipidaemia, smoking) in the non-PPI and PPI groups
(Supplementary Tables 1A–D).
Risk of Bias
The Newcastle–Ottawa quality assessment scale (Wells et al.,
2013) has been edited to our study design, and was used to
assess the quality of observational studies and post-hoc analyses
of randomized controlled trials (RCTs) (For further details see
Supplementary Material, Supplementary Figure 7B). We used
the Cochrane risk of bias tool (Higgins et al., 2011) for quality
assessment of RCTs (Supplementary Figure 7A).
Statistical Analysis
We calculated risk ratio/relative risk (RR) and 95% confidence
interval (CI) for CV events (MACE, MI and CV death).
As secondary analyses, we calculated pooled hazard ratios
and 95% CI for the adjusted events for all three major
outcomes (Supplementary Figures 4–6). Between-study
heterogeneity was tested with the I2 statistic, where I2 is the
proportion of total variation attributable to between-study
variability. I2 heterogeneity was interpreted according to the
Cochrane Handbook for Systematic Reviews and Interventions
recommendation: 0–40%: might not be important; 30–60%:
may represent moderate heterogeneity; 50–90%: may represent
substantial heterogeneity; 75–100%: considerable heterogeneity
(Higgins and Green, 2011). Fixed or random effects models were
used for comparison between the two groups (clopidogrel alone
or clopidogrel plus PPI), based on the degree of heterogeneity,
or based on methodological factors such as difference between
study designs or applied PPIs, not homogeneous patient
population etc. We estimated the effect of follow up and age on
the risk of the three major outcomes by performing random
effects meta-regression expressed as standard error and 95%
CI. P-values of <0.05 for relative risks and standard errors,
and p-values of <0.10 for heterogeneity were considered as
indicators of significance. We estimated publication bias through
a visual inspection of funnel plots (Figures 5A–C). The statistical
analysis was performed by a trained biostatistician (TL). All
analyses were performed with the Review Manager (RevMan)
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software, Version 5.3 (Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2014).
RESULTS
Study Selection
Two hundred and thirty-six articles were identified in the
preliminary search. One hundred and ninety-three studies were
excluded (Figure 1). Seventy-six publications (25 full texts, 10
abstracts, and 41 articles from previous meta-analyses) were
assessed for eligibility and qualitative synthesis. Forty-seven of
them were excluded due to insufficient data on study groups and
another two for statistical reasons (the event rate was zero). A
total of 27 studies (Rassen et al., 2009; Bhatt et al., 2010; Cai et al.,
2010; Charlot et al., 2010; Evanchan et al., 2010; Gupta et al.,
2010; Hudzik et al., 2010; Kreutz et al., 2010; Ray et al., 2010;
Stockl et al., 2010; van Boxel et al., 2010; Hsu et al., 2011; Ren
et al., 2011; Rossini et al., 2011; Simon et al., 2011; Burkard et al.,
2012; Chitose et al., 2012; Goodman et al., 2012; Ng et al., 2012;
Yano et al., 2012; Hokimoto et al., 2014; Shih et al., 2014; Zou
et al., 2014; Weisz et al., 2015; Ayub et al., 2016; Gargiulo et al.,
2016) were selected for quantitative analyses. The researchers and
committee involved in the selection (5 investigators) were in total
agreement on all the inclusions and exclusions.
Study Characteristics
Altogether, we found data for MACE in 23 publications
(O’Donoghue et al., 2009; Bhatt et al., 2010; Cai et al., 2010;
Charlot et al., 2010; Gupta et al., 2010; Hudzik et al., 2010; Kreutz
et al., 2010; Ray et al., 2010; van Boxel et al., 2010; Hsu et al., 2011;
Ren et al., 2011; Rossini et al., 2011; Simon et al., 2011; Burkard
et al., 2012; Chitose et al., 2012; Goodman et al., 2012; Ng et al.,
2012; Yano et al., 2012; Hokimoto et al., 2014; Zou et al., 2014;
Weisz et al., 2015; Ayub et al., 2016; Gargiulo et al., 2016), for CV
death in 10 (Rassen et al., 2009; Bhatt et al., 2010; Gupta et al.,
2010; Simon et al., 2011; Burkard et al., 2012; Chitose et al., 2012;
Goodman et al., 2012; Hokimoto et al., 2014; Zou et al., 2014;
Weisz et al., 2015; Gargiulo et al., 2016) and for MI in 14 (Rassen
et al., 2009; Bhatt et al., 2010; Evanchan et al., 2010; Hudzik et al.,
2010; Stockl et al., 2010; van Boxel et al., 2010; Simon et al., 2011;
Burkard et al., 2012; Chitose et al., 2012; Goodman et al., 2012;
Shih et al., 2014; Zou et al., 2014; Weisz et al., 2015; Gargiulo
et al., 2016). Seventeen of them were observational studies, 16
were cohorts (Rassen et al., 2009; Charlot et al., 2010; Evanchan
et al., 2010; Gupta et al., 2010; Kreutz et al., 2010; Ray et al., 2010;
Stockl et al., 2010; van Boxel et al., 2010; Rossini et al., 2011;
Simon et al., 2011; Chitose et al., 2012; Hokimoto et al., 2014; Shih
et al., 2014; Zou et al., 2014; Weisz et al., 2015; Ayub et al., 2016),
and one was a case-control study (Hudzik et al., 2010). Data
from 10 RCTs (O’Donoghue et al., 2009; Bhatt et al., 2010; Cai
et al., 2010; Hsu et al., 2011; Ren et al., 2011; Burkard et al., 2012;
Goodman et al., 2012; Ng et al., 2012; Yano et al., 2012; Gargiulo
et al., 2016) were also collected. As post-hoc analyses of RCTs,
in four studies (O’Donoghue et al., 2009; Burkard et al., 2012;
Goodman et al., 2012; Gargiulo et al., 2016) the populations and
outcome of our interest (clopidogrel plus PPI vs. clopidogrel plus
non-PPI treatment) were not randomized, therefore, their data
were included in the statistical analyses of observational studies.
The method and the study selection are shown in Figure 1. All
the studies included were published between 2009 and 2016. The
characteristics of the studies involved in the meta-analysis are
summarized in Table 1 according to the major outcome groups,
and in Supplementary Tables 1A–D.
The number of patients involved was 156,823. A total of
63,756 received PPI plus clopidogrel treatment (ranging from
18 to 6,843), and 99,910 (ranging from 20 to 17,949) were in
the clopidogrel alone group. Risk of MACE was determined
from data from 127,695 patients, MI risk was assessed on the
basis of data from 82,330 patients, and risk of CV death was
evaluated based on data from 53,905 patients. The PPIs used
in the studies were esomeprazole, omeprazole, pantoprazole,
rabeprazole, and lansoprazole, but in this meta-analysis as a
subgroup analysis we only drew conclusions on the results for
omeprazole, esomeprazole, and pantoprazole due to the low
number of studies separating data for different PPIs.
Major Adverse Cardiac Event
Twenty-three studies (O’Donoghue et al., 2009; Bhatt et al., 2010;
Cai et al., 2010; Charlot et al., 2010; Gupta et al., 2010; Hudzik
et al., 2010; Kreutz et al., 2010; Ray et al., 2010; van Boxel et al.,
2010; Hsu et al., 2011; Ren et al., 2011; Rossini et al., 2011; Simon
et al., 2011; Burkard et al., 2012; Chitose et al., 2012; Goodman
et al., 2012; Ng et al., 2012; Yano et al., 2012; Hokimoto et al.,
2014; Zou et al., 2014; Weisz et al., 2015; Ayub et al., 2016;
Gargiulo et al., 2016) reported the incidence of MACE. Our
results showed that the risk of MACE is significantly higher in
the PPI group (RR = 1.22, 95% CI = 1.06–1.39, p=0.004), with
considerable heterogeneity across the studies included (I2 = 90%,
p < 0.001). However, separating the data for the RCT studies
from that of the non-RCT studies revealed that a significant
association of adverse outcomes (MACE) can only be seen
in non-randomized studies (observational studies: RR = 1.26,
95% CI = 1.09–1.46, p = 0.002, I2 = 93%, p < 0.001; RCTs:
RR = 0.99, 95% CI = 0.76–1.28; I2 = 0%, p = 0.93), although
the heterogeneity remained considerable in the observational
group, whichmight not be relevant in the RCT group (Figure 2A,
Supplementary Figure 1A). As the result of meta-regression
analyses, MACE was not depending on the length of follow up
(SE = 0.007, 95% CI = −0.014 to 0.014, p = 0.97), based on the
results of 18 studies (Bhatt et al., 2010; Charlot et al., 2010; Gupta
et al., 2010; Hudzik et al., 2010; Ray et al., 2010; van Boxel et al.,
2010; Hsu et al., 2011; Simon et al., 2011; Burkard et al., 2012;
Chitose et al., 2012; Goodman et al., 2012; Ng et al., 2012; Yano
et al., 2012; Hokimoto et al., 2014; Zou et al., 2014; Weisz et al.,
2015; Ayub et al., 2016; Gargiulo et al., 2016), and the age of the
patients did not influence the occurrence of the outcome either
(SE = 0.023, 95% CI = −0.011 to 0.081, p = 0.14), based on the
data found in 19 studies (O’Donoghue et al., 2009; Bhatt et al.,
2010; Charlot et al., 2010; Gupta et al., 2010; Hudzik et al., 2010;
Ray et al., 2010; van Boxel et al., 2010; Hsu et al., 2011; Simon
et al., 2011; Burkard et al., 2012; Chitose et al., 2012; Goodman
et al., 2012; Ng et al., 2012; Yano et al., 2012; Hokimoto et al., 2014;
Zou et al., 2014; Weisz et al., 2015; Ayub et al., 2016; Gargiulo
et al., 2016).
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TABLE 1 | Study characteristics.
References, year Study type Number of
patients
PPI
(generic name)
PPI
(number of
patients)
Event number:
MACE
(PPI group)
Event number:
CV death
(PPI group)
Event number:
MI
(PPI group)
Ng et al., 2012 RCT 311 Esomeprazole 163 7
Yano et al., 2012 RCT 130 Omeprazole 65 8
Hsu et al., 2011 RCT 42 Esomeprazole 21 4
Ren et al., 2011 RCT 172 Omeprazole 86 22
Bhatt et al., 2010 RCT 3,761 Omeprazole 1,876 55 5 14
Cai et al., 2010 RCT 60
Omeprazole
Pantoprazole
40 10
Gargiulo et al., 2016 RCT
(post-hoc analysis)
1,970
Pantoprazole
Lansoprazole
Omeprazole,
esomeprazole,
rabeprazole
738
56
671
11
85 29 41
Burkard et al., 2012 RCT
(post-hoc analysis)
801
Esomeprazole
Pantoprazole
Omeprazole
109
55
27
19
33 10 25
Goodman et al., 2012 RCT
(post-hoc analysis)
9,276
Omeprazole
Pantoprazole
Esomeprazole
Lansoprazole
Rabeprazole
3,255
1,592
973
387
251
51
398 180 245
O’Donoghue et al.,
2009
RCT
(post-hoc analysis)
13,608
Omeprazole
Pantoprazole
Lansoprazole
Esomeprazole
4,529
1,675
1,844
441
613
255
Ayub et al., 2016 Observational
cohort
740 Omeprazole
Esomeprazole
Pantoprazole
332
40
81
30
6
10
Weisz et al., 2015 Observational
cohort
8,581 NS 2,162 238 58 100
Hokimoto et al., 2014 Observational
cohort
174 Rabeprazole 50 5
Shih et al., 2014 Observational
cohort
2,703 NS 1,351 12
Zou et al., 2014 Observational
cohort
7,653
Omeprazole
Pantoprazole
Esomeprazole
6,188
5,587
407
194
860 223 132
Chitose et al., 2012 Observational
cohort
630 NS 187 7 4 1
Rossini et al., 2011 Observational
cohort
1,328
Lansoprazole
Pantoprazole
Omeprazole
1,158
853
178
125
87
Simon et al., 2011 Observational
cohort
2,353
Omeprazole
Esomeprazole
Pantoprazole
Lansoprazole
1,453
993
311
99
46
43
20
12
1
94 24
Charlot et al., 2010 Observational
cohort
24,702 NS 6,753 1058
Evanchan et al., 2010 Observational
cohort
5,794
Esomeprazole
Lansoprazole
Omeprazole
Pantoprazole
1,369
749
36
163
693
356
(Continued)
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TABLE 1 | Continued
References, year Study type Number of
patients
PPI
(generic name)
PPI
(number of
patients)
Event number:
MACE
(PPI group)
Event number:
CV death
(PPI group)
Event number:
MI
(PPI group)
Gupta et al., 2010 Observational
cohort
315
Rabeprazole,
omeprazole,
lansoprazole
72 40 14
Hudzik et al., 2010 Observational
case-control
38 Omeprazole 18 10 6
Kreutz et al., 2010 Observational
cohort
16,690
Omeprazole
Pantoprazole
Lansoprazole
Esomeprazole
6,828
2,307
1,653
785
3257
1710
Ray et al., 2010 Observational
cohort
16,221
Omeprazole
Pantoprazole
Lansoprazole,
rabeprazole,
esomeprazole
7,226
683
4,708
461
Stockl et al., 2010 Observational
cohort
2,066
Pantoprazole
Rabeprazole
Omeprazole
Lansoprazole
Esomeprazole
1,033
659
159
86
83
46
133
van Boxel et al., 2010 Observational
cohort
18,139
Omeprazole
Pantoprazole
Esomeprazole
Rabeprazole
Lansoprazole
5,734
1,826
2,618
1,092
133
754 84
Rassen et al., 2009 Observational
cohort
18,565
Omeprazole,
rabeprazole,
esomeprazole,
lansoprazole,
pantoprazole
3,996 61 238
CV, cardiovascular; MACE, major adverse cardiac event; MI, myocardial infarction; NS, not shown/not specified; PPI, proton pump inhibitor; RCT, randomized controlled trial.
In case of patients on omeprazole among the 6 publications
included (Bhatt et al., 2010; Hudzik et al., 2010; Ren et al.,
2011; Simon et al., 2011; Yano et al., 2012; Ayub et al., 2016),
there was no significant difference between the clopidogrel
plus PPI and clopidogrel alone groups (RR = 0.80, 95%
CI = 0.50–1.28, p = 0.35), but since there was evidence
of considerable heterogeneity (I2 = 81%, p < 0.001), the
random effect model was used for comparison (Figure 2B,
Supplementary Figure 1B). In the case of esomeprazole (4
publications, Hsu et al., 2011; Simon et al., 2011; Ng et al.,
2012; Ayub et al., 2016), results showed no significant
difference in the occurrence of MACE between the groups
(RR = 0.73, 95% CI = 0.51–1.05, p = 0.09) (Figure 2B,
Supplementary Figure 1B). The heterogeneity might not be
important (I2 = 0%, p = 0.41); the fixed effects model was used
for comparison. In the pantoprazole group, we only found two
eligible publications (Simon et al., 2011; Ayub et al., 2016) for
MACE, and there was no difference between the two groups
(RR = 0.91, 95% CI = 0.60–1.39, p = 0.66) (Figure 2B,
Supplementary Figure 1B). The heterogeneity might not be
important (I2 = 0%, p = 0.34); the fixed effects model was used
in analyzing of this specific PPI. The results of analyzing the
adjusted events for the overall outcome and for different PPIs are
presented as Supplementary Material.
Cardiovascular Death
Data on CV death was reported in 10 studies (Rassen et al., 2009;
Bhatt et al., 2010; Gupta et al., 2010; Simon et al., 2011; Burkard
et al., 2012; Chitose et al., 2012; Goodman et al., 2012; Zou et al.,
2014; Weisz et al., 2015; Gargiulo et al., 2016), including 53,905
patients; only one study’s data was evaluated as RCT (Bhatt et al.,
2010). There was no significant effect of concomitant clopidogrel
and PPI treatment on CV death (RR= 1.21, 95% CI= 0.97–1.50,
p = 0.09). The result from the statistical analysis may represent
substantial heterogeneity across the studies (I2= 67%, p= 0.001).
The length of follow up and the age of the patients did not affect
the risk for CV death based on results of the included 10 studies
(follow up: SE= 0.009, 95% CI= −0.016 to 0.021, p= 0.81; age:
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FIGURE 2 | Forrest plots representing the estimated risk of overall major adverse cardiac events (A) and in case of taking specific proton pump inhibitors (B) CI,
confidence interval; PPI, proton pump inhibitor; RCT, randomized controlled trials.
Frontiers in Physiology | www.frontiersin.org 7 November 2018 | Volume 9 | Article 1550
Demcsák et al. Clopidogrel Plus PPIs: Cardiovascular Outcomes
FIGURE 3 | Forrest plot representing the estimated risk of cardiovascular death. CI, confidence interval; PPI, proton pump inhibitor; RCT, randomized controlled trials.
SE= 0.022; 95% CI=−0.009 to 0.079, p= 0.12). Unfortunately,
the low amount of data prevented us from evaluating the risk of
CV death in specific PPIs (Figure 3, Supplementary Figure 2).
Analysis of the adjusted events for CV death can be found in the
Supplementary Material.
Myocardial Infarction
Fourteen of the twenty-seven studies contained eligible data
on MI, with data for 82,330 patients for evaluation (Rassen
et al., 2009; Bhatt et al., 2010; Evanchan et al., 2010; Hudzik
et al., 2010; Stockl et al., 2010; van Boxel et al., 2010; Simon
et al., 2011; Burkard et al., 2012; Chitose et al., 2012; Goodman
et al., 2012; Shih et al., 2014; Zou et al., 2014; Weisz et al.,
2015; Gargiulo et al., 2016); one study’s data was evaluated
as RCT (Bhatt et al., 2010). The risk of MI was significantly
higher in the PPI group (RR = 1.43, 95% CI = 1.24–
1.66, p < 0.001). The results from the statistical analysis may
represent substantial heterogeneity across the studies (I2 = 66%,
p < 0.001) (Figure 4A, Supplementary Figure 3A). Similarly to
MACE and CV death, MI was not depending on the length
of follow up or on the patients’ age based on the included
fourteen studies (follow up: SE = 0.005, 95% CI = −0.005
to 0.013, p = 0.41; age: SE = 0.013, 95% CI = −0.045 to
0.007, p = 0.15). We only found two eligible articles (Bhatt
et al., 2010; Hudzik et al., 2010) for MI in the case of
omeprazole, where there was no difference in risk between
the observed groups (RR = 1.98, 95% CI = 0.31–12.76,
p = 0.47). There may be substantial heterogeneity across the
studies (I2 = 69%, p = 0.07); the random effects model
was used (Figure 4B, Supplementary Figure 3B). We present
the result for the analysis of adjusted MI events in the
Supplementary Material.
Risk of Bias Within Studies
Risk of bias was assessed in 17 non-RCT studies (Rassen et al.,
2009; Charlot et al., 2010; Evanchan et al., 2010; Gupta et al., 2010;
Hudzik et al., 2010; Kreutz et al., 2010; Ray et al., 2010; Stockl
et al., 2010; van Boxel et al., 2010; Rossini et al., 2011; Simon et al.,
2011; Chitose et al., 2012; Hokimoto et al., 2014; Shih et al., 2014;
Zou et al., 2014; Weisz et al., 2015; Ayub et al., 2016), four post-
hoc analyses of RCTs (O’Donoghue et al., 2009; Burkard et al.,
2012; Goodman et al., 2012; Gargiulo et al., 2016), and in six RCTs
(Bhatt et al., 2010; Cai et al., 2010; Hsu et al., 2011; Ren et al.,
2011; Ng et al., 2012; Yano et al., 2012). The risk of bias within the
27 studies included in this meta-analysis is summarized in the
Supplementary Figures 7A,B.
Publication Bias
Funnel plots were constructed for each outcome and showed
symmetry on visual inspection, suggesting that publication
bias was not large and was unlikely to alter conclusions
(Figures 5A–C).
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FIGURE 4 | Forrest plots representing the estimated risk of overall myocardial infarction (A) and in case of applying omeprazole as proton pump inhibitor (B) CI,
confidence interval; PPI, proton pump inhibitor; RCT, randomized controlled trials.
DISCUSSION
A possible interaction between clopidogrel and PPIs came
to the fore after an observational study had been performed
in 2006, which found clopidogrel activity on platelets was
diminished in patients receiving PPI treatment (Gilard et al.,
2006). Later, this potential interaction was tested in the
randomized controlled OCLA (Omeprazole CLopidogrel
Aspirin) study, where omeprazole significantly decreased the
effect of clopidogrel on in vitro platelet activation (Gilard et al.,
2008).
Clopidogrel, a thienopyridine derivative, inhibits platelet
aggregation through irreversible inhibition of the ADP/P2Y12
receptor on the surface of platelets, and, being a prodrug, it
requires a two-step oxidative biotransformation intrahepatically,
mediated mainly by cytochrome P450 isoenzymes. First, the
cytochrome P450 isoenzymes CYP1A2, CYP2B6, and CYP2C19
form 2-oxo-clopidogrel, which is then oxidized by CYP2B6,
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FIGURE 5 | Funnel plots for studies in major adverse cardiac event (A), in
cardiovascular death (B) and in myocardial infarction (C) groups.
CYP2C19, CYP2C9, and CYP3A4 to the active metabolite
of clopidogrel, with CYP2C19 being the most important
isoenzyme. The active metabolite then binds irreversibly
to platelet adenosine diphosphate receptor P2Y12 (Hulot
et al., 2006; Disney et al., 2011; Tantry et al., 2011), therefore
preventing platelet aggregation. This is associated with the
dephosphorylation of the intraplatelet vasodilator-stimulated
phosphoprotein. Vasodilator-stimulated phosphoprotein
phosphorylation provides an index to evaluate platelet reactivity
to clopidogrel (Ward and Kearns, 2013). The findings on
mechanisms underlying clopidogrel resistance are contradictory;
these mechanisms may relate to heterogeneity in clopidogrel
metabolism. CYP2C19 activity can have a profound effect on the
conversion of clopidogrel to its active metabolite (Hulot et al.,
2006).
All PPIs are extensively metabolized to inactive metabolites
mainly via CYP2C19 and CYP3A4 in the liver. Rabeprazole
uses these enzymes the least, being mostly converted to its
thioether analog non-enzymatically. The potency and specificity
of five individual PPIs (omeprazole, esomeprazole, pantoprazole,
lansoprazole, rabeprazole) with regard to their inhibitory effects
on the activities of four major human CYP enzymes (CYP2C9,
CYP2C19, CYP2D6, and CYP3A4) have been studied by Li
et al (Li et al., 2004). Lansoprazole was the most potent
inhibitor of CYP2C19 enzyme in vitro, followed by omeprazole
and esomeprazole. Pantoprazole showed the lowest potential
to CYP2C19, however it was at least twice as potent an
inhibitor as other PPIs toward CYP2C9 and CYP3A4. As the
metabolite of rabeprazole, rabeprazole thioether was a strong and
competitive inhibitor of CYP2C9, CYP2C19, and CYP2D6. It has
been suggested that rabeprazole has significantly less drug-drug
interactions than other PPIs, and the main reason is claimed to
be its non-enzyme catalyzed degradation, but the results of Li et
al suggest that omeprazole and rabeprazole have similar affinity to
CYP3A4 (Li et al., 2004; Ogawa and Echizen, 2010). The potential
interaction mechanism lies in the fact that both clopidogrel
and PPIs, in varying degrees, are metabolized by the same
cytochrome P450 enzyme (CYP2C19). PPIs have the potential to
competitively inhibit the metabolism of clopidogrel to its active
metabolite, which leads to reduced circulating concentrations of
the active compound (Disney et al., 2011).
The data on the interactions between clopidogrel and PPIs
remain unclear despite the numerous in vitro and in vivo
studies on the subject. The in vitro studies have shown that the
effectiveness of clopidogrel decreases with simultaneous use of
clopidogrel and PPIs (Gilard et al., 2008), and, therefore, the
risk for CV events will be elevated. Several possible causative
factors may lie behind this phenomenon. One of them is the
connected bio-transformational route of clopidogrel and PPIs,
or the possible differences in genetic polymorphism of these
enzymes (Hulot et al., 2006). There are several studies, mostly
observational ones, whose findings are consistent with these
in vitro results, showing an elevated risk for CV side-effects in
patients on combined clopidogrel and PPI treatment (Pezalla
et al., 2008; Ho et al., 2009; Juurlink et al., 2009; Kreutz et al.,
2010). However, it should be noted that prophylactic PPIs are
more likely prescribed to patients with a higher risk for CV events
(Disney et al., 2011).
There is considerable disagreement between the various
clinical studies that show no increased risk of CV outcomes
(O’Donoghue et al., 2009; Rassen et al., 2009; Bhatt et al., 2010;
Ray et al., 2010; Zairis et al., 2010). Furthermore, a few studies
found no difference in the possible disadvantageous effect of PPI
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drugs causing extended inhibition of CYP2C19 (O’Donoghue
et al., 2009; Zairis et al., 2010). In several cases, the authors used
multivariable adjustments for covariates to standardize because
the effect of possible factors (such as age, co-morbidities, and
co-medication) could modify the outcomes (Rassen et al., 2009;
Valkhoff et al., 2011). In a well-designed case-control study, a
current PPI plus clopidogrel group result was compared to the
results for patients on current clopidogrel plus past PPI therapy.
The association between PPI therapy and the recurrence of MI
has disappeared suggesting that the appearance of recurrent MI
is a result of a residual confounding (Valkhoff et al., 2011).
Based on the ACCF/ACG/AHA 2010 Expert Consensus
Document (Abraham et al., 2010) to reduce the risk of GI
bleeding, PPIs are recommended among patients with history of
upper GI bleeding or with multiple risk factors (e.g., advanced
age, concomitant use of warfarin, steroid or NSAIDs, or H.
pylori infection) for GI bleeding who require antiplatelet therapy.
Patients with acute coronary syndrome and prior upper GI
bleeding are at substantial CV risk, so dual antiplatelet therapy
with concomitant use of a PPI may provide the optimal
balance of risk and benefit. The risk reduction achieved by
concomitant PPIs might outweigh any potential reduction in
the CV efficacy of antiplatelet treatment because of a drug–
drug interaction. Routine use of acid suppressant drugs is not
recommended for patients at lower risk of upper GI bleeding,
who have much less potential to benefit from prophylactic
therapy. Clinical decisions regarding concomitant use of PPIs
and thienopyridines must be based on whether the potential
for benefit outweighs the potential for harm, considering both
CV and GI complications. Furthermore, according to the
European Cardiology Society’s 2017 guideline (Ibanez et al.,
2018) for the management of acute myocardial infarction
in patients presenting with ST-segment elevation a PPI in
combination with dual antiplatelet therapy is recommended
(I/B recommendation) in patients at high risk of GI bleeding.
Based on the recent European Society of Cardiology/European
Association for Cardio-Thoracic Surgery guidelines (Neumann
et al., 2018) on myocardial revascularization every effort should
be undertaken such as routine use of PPIs to avoid bleeding in
patients after percutaneous coronary intervention requiring oral
anticoagulation and dual antiplatelet therapy. These statements
have been supported by several studies which showed that the risk
of upper GI bleeding can be reduced in patients with clopigodrel
by concomitant PPI treatment. The occurrence of GI bleeding
were 0.2–1.2% (Bhatt et al., 2010), 0–2% (Chitose et al., 2012),
0.4–1.8% (Mo et al., 2015) in the PPI vs. non-PPI groups,
respectively.
In this meta-analysis, our aim was to focus on this discrepancy
and to find a possible resolution. Our combined data from all
of the studies involved showed that the presence of MACE and
MI is significantly higher in the PPI plus clopidogrel patient
population, a finding which is consistent with results from
previous observational studies (Ho et al., 2009; Juurlink et al.,
2009; Charlot et al., 2010; Gupta et al., 2010; Hudzik et al.,
2010; van Boxel et al., 2010). However, in reducing the degree
of heterogeneity by creating subgroups based on study design,
we also found that this previously experienced risk elevation
and heterogeneity will disappear as in other studies (Kwok and
Loke, 2010). This result is similar to those of previous meta-
analyses, where a higher CV risk was found among observational
studies without any difference between the clopidogrel plus PPI
group and the no PPI group in RCTs (Chen et al., 2012). In
previousmeta-analyses byMo et al. (2015) and Chen et al. (2013),
data only collected from RCTs showed no correlation between
simultaneous clopidogrel and PPI therapy and elevated CV risk.
An examination of the results, heterogeneity and risk of bias
of the studies involved in our meta-analysis points to the low
quality of observational studies, whose results are opposite to
those of RCT studies, all proving an acceptance of results from
RCT studies showing no enhancement of CV risks due to PPIs.
Although our meta-analysis has shown that there is no
association between CV risk elevation and PPI usage, our analysis
might have limitations. One is that in the 22 studies included,
the population had previously had CV diseases, had already
undergone percutaneous coronary intervention, or had received
dual antiplatelet therapy, meaning that the population under
examination may have had severe conditions. In this meta-
analysis, we did not analyze the effect of these or other co-
morbidities nor evaluate their conditions, but it is possible that
the harmful effect of PPIs may be different in patients who need
primary or secondary CV prevention. Although we performed
secondary analyses on adjusted events, the conclusions drawn
from these analyses are limited, because of the insufficient
availability of these values across all studies, which were all
observational ones, and the applied covariates were different
among them. The studies published and available in the databases
provided poor descriptions of other risk factors (such as co-
morbidities, co-medications, smoking, obesity etc.), preventing
us from providing a summary or conclusion in that regard. The
other limitation of our study is the substantial heterogeneity
among the studies, which may stem from several factors, such
as differences in study design. In observational studies or
in post-hoc analyses of RCTs, the groups were not allocated
randomly. It was usually the physicians’ decision, so this most
likely led to a distortion of the results. Therefore, risk of bias
within studies should be highlighted, as well. Though the open-
label design might have a less prominent effect on hard CV
outcomes, lack of blinding should be mentioned, even in RCTs.
In addition, incomplete follow-up and not carefully applied
objective evaluation of ascertainment of drug exposures may
impose additional risk of bias. Bias is inherent in observational
studies, the subgroup analysis of RCTs and observational studies
yielding discrepant results support this statement. And there is a
problem with the definition of MACE, which is not standard in
the literature, although it is most often used to express the CV
risk of PPIs plus clopidogrel.
Our aim was to draw conclusion from data for a large patient
population; we therefore included as many observational studies
as the inclusion criteria permitted despite their limitations.
Patients were selected from various ethnic groups; they thus
represent the world population. With a few years having passed
since previous meta-analyses were published on the subject (the
last study in these meta-analyses having been published in 2014)
(Mo et al., 2015; Sherwood et al., 2015; Serbin et al., 2016), and
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with new studies having been carried out since then, we were
prompted to perform this systematic search and meta-analysis to
re-evaluate the risks.
CONCLUSION
Our meta-analysis has shown that there is no definitive evidence
for any significant association between CV risk elevation and PPI
in patients on clopidogrel treatment, based on RCTs. Thus, no
definitive evidence exists for an effect on mortality. From this
point of view, the previous FDA guidance to use favorable or
non-favorable drug combinations does not seem to be relevant
by now based on both previous trials (e.g., COGENT, TRITON-
TIMI) and our own analyses. However, taking into account
the bias, this meta-analysis should be interpreted with caution,
and conducting further RCTs would be beneficial. Because PPI
induced risk reduction clearly outweighs the possible adverse CV
risk in patients with a high risk of GI bleeding, a combination of
clopidogrel with PPI should be recommended.
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